New oral GLP-1s are changing the weight loss game. Here is what you need to know before recommending or dispensing one.

In this episode, TRC Healthcare Associate Editor and Clinical Pharmacist Vickie Danaher, PharmD, discusses how orforglipron, the second oral GLP-1 agonist for weight loss, stacks up against oral semaglutide in terms of dosing, efficacy, safety, and more.

This is an excerpt from our May 2026 Pharmacy Essential Updates continuing education webinar series.

🏷️ Use code cc1026 at checkout for 10% off a new or upgraded subscription.

******

CE Information:

TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.

Claim Credit

******

Clinical Resources from Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:

• Article: Be Ready for the New Oral GLP-1 Agonist Orforglipron
• Chart: GLP-1 and GIP/GLP-1 Receptor Agonist Interactive Comparison Chart
• Chart: Comparison of Weight Loss Products

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

🗪 Send us Fan Mail

Email us: ContactUs@trchealthcare.com.

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.